Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering of 24.6 million primary shares.
Global Capital Asia reports that Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering (IPO) of 24.6 million primary shares.
CEO of Celltrion Healthcare, Kim Man-Hoon, has announced that the Korean biosimilar maker is seeking additional drug candidates as it leverages its newly raised funds to broaden its product portfolio. According to Bio Spectrum Asia, Celltrion’s expansion will include international investment, strategic acquisition, joint ventures, and licensing partnerships with new drug developers as the company expands and capitalizes on its already robust pipeline. “We have plans to launch a major biosimilar every year until 2019,” Kim said.
Kim went on to indicate that among the company’s chief aims is the acquisition of US-based biotechnology companies as Celltrion expands its presence in the lucrative US marketplace. “By taking over US biotech firms, we expect to boost Celltrion Healthcare’s brand awareness and market share,” said Kim.
The biosimilar manufacturer, which announced that it had submitted to the FDA its Biologics License Application (BLA) for a proposed biosimilar rituximab product in June, reports 6 biosimilars currently under development:
The company is also developing 5 innovator biologics for influenza, rabies, hepatitis B virus, and others.
The successful IPO is welcome news to the Incheon-based company that, earlier this year, had to delay its offering after local regulators and accountants demanded a comprehensive audit of the company’s accounting practices. In March, the Korean Institute of Certified Public Accountants, a body that reviews the eligibility of firms to offer shares, found that Celltrion Healthcare had overstated its profits by approximately $8.94 million.
While many in the industry feared that the audit would set the biosimilar manufacturer’s IPO back by 6 months or more, Celltrion Healthcare confidently—and correctly—predicted that the process would not have a significant impact on its timeline for launching the IPO.
Celltrion’s stock will begin trading on the Korean market on July 28, and is expected to be the second most valuable company on the Kosdaq index.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.